GLP-1 receptor agonists use in youth with type 2 diabetes tied to decreased HbA1c levels: Study
USA: Real-world use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) in children and adults between the ages of 11 and 23 with type 2 diabetes (T2D) is associated with decreased HbA1c levels, despite challenges with adherence and access, a recent study has shown. The findings, published in Diabetes, Obesity and Metabolism, suggest that GLP-1RA treatment may […]